GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (MEX:MRNA) » Definitions » Piotroski F-Score

Moderna (MEX:MRNA) Piotroski F-Score : 3 (As of Dec. 11, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Moderna Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Moderna has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Moderna's Piotroski F-Score or its related term are showing as below:

MEX:MRNA' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 7
Current: 3

During the past 8 years, the highest Piotroski F-Score of Moderna was 7. The lowest was 2. And the median was 4.


Moderna Piotroski F-Score Historical Data

The historical data trend for Moderna's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Piotroski F-Score Chart

Moderna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial 3.00 4.00 7.00 5.00 3.00

Moderna Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 3.00 2.00 3.00

Competitive Comparison of Moderna's Piotroski F-Score

For the Biotechnology subindustry, Moderna's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moderna's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moderna's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Moderna's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Net Income was 3683.412 + -19500.6 + -23431.412 + 255.974 = MXN-38,993 Mil.
Cash Flow from Operations was 10557.982 + -16413.696 + -23339.811 + -30835.01 = MXN-60,031 Mil.
Revenue was 47748.56 + 2771.575 + 4048.743 + 36525.507 = MXN91,094 Mil.
Gross Profit was 31979.483 + 1178.334 + 1941.931 + 26404.692 = MXN61,504 Mil.
Average Total Assets from the begining of this year (Sep23)
to the end of this year (Sep24) was
(338797.547 + 312767.493 + 277638.75 + 287259.215 + 311165.811) / 5 = MXN305525.7632 Mil.
Total Assets at the begining of this year (Sep23) was MXN338,798 Mil.
Long-Term Debt & Capital Lease Obligation was MXN25,676 Mil.
Total Current Assets was MXN190,326 Mil.
Total Current Liabilities was MXN43,338 Mil.
Net Income was 28561.64 + 1423.975 + -23658.582 + -63230.596 = MXN-56,904 Mil.

Revenue was 100384.904 + 33129.95 + 5417.472 + 31127.569 = MXN170,060 Mil.
Gross Profit was 62991.576 + 18854.15 + -7114.719 + -7908.179 = MXN66,823 Mil.
Average Total Assets from the begining of last year (Sep22)
to the end of last year (Sep23) was
(524116.44 + 504127.568 + 434853.125 + 375177.108 + 338797.547) / 5 = MXN435414.3576 Mil.
Total Assets at the begining of last year (Sep22) was MXN524,116 Mil.
Long-Term Debt & Capital Lease Obligation was MXN22,157 Mil.
Total Current Assets was MXN188,107 Mil.
Total Current Liabilities was MXN76,382 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Moderna's current Net Income (TTM) was -38,993. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Moderna's current Cash Flow from Operations (TTM) was -60,031. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep23)
=-38992.626/338797.547
=-0.11509123

ROA (Last Year)=Net Income/Total Assets (Sep22)
=-56903.563/524116.44
=-0.10857046

Moderna's return on assets of this year was -0.11509123. Moderna's return on assets of last year was -0.10857046. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Moderna's current Net Income (TTM) was -38,993. Moderna's current Cash Flow from Operations (TTM) was -60,031. ==> -60,031 <= -38,993 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep23 to Sep24
=25676.151/305525.7632
=0.08403923

Gearing (Last Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=22156.837/435414.3576
=0.05088679

Moderna's gearing of this year was 0.08403923. Moderna's gearing of last year was 0.05088679. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep24)=Total Current Assets/Total Current Liabilities
=190326.44/43338.35
=4.3916402

Current Ratio (Last Year: Sep23)=Total Current Assets/Total Current Liabilities
=188106.669/76381.863
=2.46271381

Moderna's current ratio of this year was 4.3916402. Moderna's current ratio of last year was 2.46271381. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Moderna's number of shares in issue this year was 399. Moderna's number of shares in issue last year was 381. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=61504.44/91094.385
=0.67517268

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=66822.828/170059.895
=0.39293702

Moderna's gross margin of this year was 0.67517268. Moderna's gross margin of last year was 0.39293702. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep23)
=91094.385/338797.547
=0.26887557

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep22)
=170059.895/524116.44
=0.32446968

Moderna's asset turnover of this year was 0.26887557. Moderna's asset turnover of last year was 0.32446968. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+0+0+1+0+1+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Moderna has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Moderna  (MEX:MRNA) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Moderna Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Moderna's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Moderna Business Description

Address
200 Technology Square, Cambridge, MA, USA, 02139
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.